Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking.Methods and...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/6/e062702.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586940187148288 |
|---|---|
| author | George A Wells Kevin Emery Boczar Sheojung Shin Kathryn A Bezzina Aishwarya Geejo Alexander Liam Pearson Saba Shahab Christophe A Fehlmann Sarah Visintini Rob Beanlands |
| author_facet | George A Wells Kevin Emery Boczar Sheojung Shin Kathryn A Bezzina Aishwarya Geejo Alexander Liam Pearson Saba Shahab Christophe A Fehlmann Sarah Visintini Rob Beanlands |
| author_sort | George A Wells |
| collection | DOAJ |
| description | Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking.Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial registry websites, Europe PMC and conference abstract handsearching. No publication date or language restrictions will be imposed. Eligible interventions must have some component of anti-inflammatory agent. These include (but are not limited to): non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, prednisone, methotrexate, canakinumab, pexelizumab, anakinra, succinobucol, losmapimod, inclacumab, atreleuton, LP-PLA2 (darapladib) and sPLA2 (varespladib). The primary outcomes will include major adverse cardiac events (MACE), and each individual component of MACE (myocardial infarction, stroke and cardiovascular death). Key secondary outcomes will include unstable angina, heart failure, all-cause mortality, cardiac arrest and revascularisation. Screening, inclusion, data extraction and quality assessment will be performed independently by two reviewers. Network meta-analysis based on the random effects model will be conducted to compare treatment effects both directly and indirectly. The quality of the evidence will be assessed with appropriate tools including the Grading of Recommendations, Assessment, Development and Evaluation profiler or Confidence in Network Meta-Analysis tool.Ethics and dissemination Ethics approval is not required for this systematic review. The findings will be disseminated through a peer-reviewed journal.PROSPERO registration number CRD42022303289. |
| format | Article |
| id | doaj-art-865c691889874f278ee42f3faaa13223 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-865c691889874f278ee42f3faaa132232025-01-24T19:50:18ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2022-062702Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trialsGeorge A Wells0Kevin Emery Boczar1Sheojung Shin2Kathryn A Bezzina3Aishwarya Geejo4Alexander Liam Pearson5Saba Shahab6Christophe A Fehlmann7Sarah Visintini8Rob Beanlands9Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, CanadaEpidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaMedicine, Elisabeth Bruyere Hospital, Ottawa, Ontario, CanadaCardiology, University of Ottawa Heart Institute, Ottawa, Ontario, CanadaCardiology, University of Ottawa Heart Institute, Ottawa, Ontario, CanadaDepartment of Medicine, University of Ottawa, Ottawa, Ontario, CanadaUniversity of Ottawa, Ottawa, Ontario, Canada8 Berkman Library, University of Ottawa Heart Institute, Ottawa, ON, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaIntroduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking.Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial registry websites, Europe PMC and conference abstract handsearching. No publication date or language restrictions will be imposed. Eligible interventions must have some component of anti-inflammatory agent. These include (but are not limited to): non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, prednisone, methotrexate, canakinumab, pexelizumab, anakinra, succinobucol, losmapimod, inclacumab, atreleuton, LP-PLA2 (darapladib) and sPLA2 (varespladib). The primary outcomes will include major adverse cardiac events (MACE), and each individual component of MACE (myocardial infarction, stroke and cardiovascular death). Key secondary outcomes will include unstable angina, heart failure, all-cause mortality, cardiac arrest and revascularisation. Screening, inclusion, data extraction and quality assessment will be performed independently by two reviewers. Network meta-analysis based on the random effects model will be conducted to compare treatment effects both directly and indirectly. The quality of the evidence will be assessed with appropriate tools including the Grading of Recommendations, Assessment, Development and Evaluation profiler or Confidence in Network Meta-Analysis tool.Ethics and dissemination Ethics approval is not required for this systematic review. The findings will be disseminated through a peer-reviewed journal.PROSPERO registration number CRD42022303289.https://bmjopen.bmj.com/content/12/6/e062702.full |
| spellingShingle | George A Wells Kevin Emery Boczar Sheojung Shin Kathryn A Bezzina Aishwarya Geejo Alexander Liam Pearson Saba Shahab Christophe A Fehlmann Sarah Visintini Rob Beanlands Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials BMJ Open |
| title | Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials |
| title_full | Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials |
| title_fullStr | Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials |
| title_full_unstemmed | Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials |
| title_short | Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials |
| title_sort | examining anti inflammatory therapies in the prevention of cardiovascular events protocol for a systematic review and network meta analysis of randomised controlled trials |
| url | https://bmjopen.bmj.com/content/12/6/e062702.full |
| work_keys_str_mv | AT georgeawells examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT kevinemeryboczar examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT sheojungshin examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT kathrynabezzina examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT aishwaryageejo examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT alexanderliampearson examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT sabashahab examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT christopheafehlmann examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT sarahvisintini examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials AT robbeanlands examiningantiinflammatorytherapiesinthepreventionofcardiovasculareventsprotocolforasystematicreviewandnetworkmetaanalysisofrandomisedcontrolledtrials |